Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02022020 · ClinicalTrials.gov registry record

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

A clinical trial of Atrial Fibrillation, sponsored by Boehringer Ingelheim.

Completed
Registry status
220
Enrollment target
20
Study locations

NCT02022020 is a study of Atrial Fibrillation that has completed, run by Boehringer Ingelheim. The registered enrollment target is 220 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02022020, a study of Atrial Fibrillation, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
220 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.

Conditions Studied

Atrial Fibrillation

Study Locations (20)

Virginia

  • Boehringer Ingelheim Investigational Site - Charlottesville
  • Boehringer Ingelheim Investigational Site - Norfolk
  • Boehringer Ingelheim Investigational Site - Roanoke

Florida

  • Boehringer Ingelheim Investigational Site - Orlando
  • Boehringer Ingelheim Investigational Site - Tampa

Missouri

  • Boehringer Ingelheim Investigational Site - Chesterfield
  • Boehringer Ingelheim Investigational Site - St Louis

New York

  • Boehringer Ingelheim Investigational Site - New York
  • Boehringer Ingelheim Investigational Site - Staten Island

Colorado

  • Boehringer Ingelheim Investigational Site - Aurora

Connecticut

  • Boehringer Ingelheim Investigational Site - New Britain

Louisiana

  • Boehringer Ingelheim Investigational Site - New Orleans

Massachusetts

  • Boehringer Ingelheim Investigational Site - Springfield

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2014-01
Est. Completion 2015-10

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02022020

The ClinicalTrials.gov registry entry for NCT02022020 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.

NCT02022020 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Virginia, Florida, Missouri.

Frequently Asked Questions

What is clinical trial NCT02022020 about?

NCT02022020 is a clinical study titled "Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa". This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.

What is the current status of trial NCT02022020?

This trial is currently completed. The enrollment target is 220 participants. The study started on 2014-01. Estimated completion is 2015-10.

What conditions does trial NCT02022020 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

Who is sponsoring clinical trial NCT02022020?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02022020 being conducted?

This trial has 20 study locations across Colorado, Connecticut, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.